课题基金 / 基金详情

Convergence Insufficiency Treatment Trial- Attention and Reading Trial (CITT-ART)

Convergence Insufficiency Treatment Trial- Attention and Reading Trial (CITT-ART)
收敛不足治疗试验 - 注意力和阅读试验(CITT-ART)
批准号:
9094732
负责人:
GLADYS L MITCHELL
金额:
$33.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-01 至 2019-04-30

项目摘要

项目成果

GLADYS L MITCHELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This is the data coordinating center's grant proposal for the Convergence Insufficiency Treatment Trial- Attention and Reading Trial (CITT-ART). The Data Coordinating Center (DCC) will be housed in the College of Optometry at The Ohio State University. The CITT-ART is a multi-center randomized clinical trial designed to evaluate the effects of treatment for symptomatic convergence insufficiency (Cl) on reading performance and attention in children. In this trial, 324 children aged 9 to <14 years with symptomatic convergence insufficiency will be randomly assigned to: 1) office-based vergence/ accommodative therapy with home-reinforcement or 2) office-based placebo therapy with home reinforcement. After 16 weeks of treatment, examiners masked to treatment group assignment will administer the primary outcome measures for: 1) reading comprehension (Wechsler Individual Achievement test [WIAT-III]) reading comprehension subtest and 2) attention (Strengths & Weaknesses of ADHD Symptoms & Normal Behavior Scale [SWAN]). The Gates MacGinitie-4 test, which uses a format similar to curriculum-based evaluation done in classrooms, will provide a secondary measure of reading comprehension. Other secondary outcome measures include: a test of reading fluency (WIATT III), the SNAP test of attention, the CI Symptom Survey, clinical measures of CI (i.e., near point of convergence and positive fusional vergence at near), and assessments of key reading and cognitive components that impact reading comprehension (pseudo word decoding, word reading, and listening comprehension). Long-term effects on reading achievement and attention will be assessed 1-year post treatment. This application provides the rationale for the design of the clinical trial ad a description of the goals and responsibilities of the DCC. This proposal also includes some results from previous studies performed by the core members of the CITT planning committee including personnel from the DCC. Symptomatic CI is a common vision disorder in children that is commonly associated with symptoms while reading (e.g. loss of place, loss of concentration, frequent re-reading, reading slowly, and trouble remembering what was read). However, the effect of CI treatment on reading and attention is unknown. The results of the proposed study will lead to a better understanding of these relationships and have important implications for educators, psychologists, and physicians who care for children with reading and attention problems. The findings will guide hypothesis development for future scientific investigations in children with vision disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Convergence Insufficiency Treatment Trial- Attention and Reading Trial (CITT-ART)
  • 批准号:
    9274969
  • 项目类别:
  • 资助金额:
    $31.26万
  • 财政年份:
    2014
  • 负责人:
    GLADYS L MITCHELL
  • 依托单位:
Convergence Insufficiency Treatment Trial- Attention and Reading Trial (CITT-ART)
  • 批准号:
    8609307
  • 项目类别:
  • 资助金额:
    $41.8万
  • 财政年份:
    2014
  • 负责人:
    GLADYS L MITCHELL
  • 依托单位:
Convergence Insufficiency Treatment Trial
  • 批准号:
    6954165
  • 项目类别:
  • 资助金额:
    $39.13万
  • 财政年份:
    2004
  • 负责人:
    GLADYS L MITCHELL
  • 依托单位:
Convergence Insufficiency Treatment Trial
  • 批准号:
    7283008
  • 项目类别:
  • 资助金额:
    $24.2万
  • 财政年份:
    2004
  • 负责人:
    GLADYS L MITCHELL
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: